

(ii) administering a vesicle composition to said patient, by continuous intravascular infusion, wherein said vesicle composition comprises, in an aqueous carrier, vesicles comprising lipids, proteins, or polymers and a gas or gaseous precursor; and

Σ1
cont. (iii) applying ultrasonic energy to the patient in an amount sufficient to produce cavitation or rupture of said vesicles, and sufficient to increase delivery of said bioactive agent from the vasculature into said selected tissue, wherein said bioactive agent is delivered into said selected tissue.

164. (Thrice amended) A method for enhancing the delivery of a bioactive agent from the vasculature to a selected tissue in a patient, said method comprising:

Σ2 (i) administering said bioactive agent to said patient;

(ii) administering an acoustically active composition to said patient, by continuous intravascular infusion; and

(iii) applying ultrasonic energy to the patient in an amount sufficient to activate said acoustically active composition, and sufficient to increase delivery of said bioactive agent from the vasculature into said selected tissue, wherein said bioactive agent is delivered into said selected tissue and said ultrasound energy has a frequency of from about 100 kHz to about 1 MHz.

REMARKS

For convenience, the Examiner's rejections are addressed in the order in which they were presented in November 14, 2002 Office Action. Appendix A shows changes made to the amended claims.